CN113185593A - DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application - Google Patents

DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application Download PDF

Info

Publication number
CN113185593A
CN113185593A CN202110539350.5A CN202110539350A CN113185593A CN 113185593 A CN113185593 A CN 113185593A CN 202110539350 A CN202110539350 A CN 202110539350A CN 113185593 A CN113185593 A CN 113185593A
Authority
CN
China
Prior art keywords
recombinant protein
rcgdm9cp
seq
crassostrea gigas
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110539350.5A
Other languages
Chinese (zh)
Inventor
王玲玲
李奕男
孙洁洁
王伟林
宋林生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Ocean University
Original Assignee
Dalian Ocean University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Ocean University filed Critical Dalian Ocean University
Priority to CN202110539350.5A priority Critical patent/CN113185593A/en
Publication of CN113185593A publication Critical patent/CN113185593A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a DM9 structural domain-containing recombinant protein rCgDM 9-9 CP-6 of crassostrea gigas, wherein an amino acid sequence is shown as SEQ ID NO. 1; the preparation method comprises the following steps in sequence: primers P1 and P2 are used for pairing crassostrea gigasCgCarrying out PCR amplification on the DM9CP-6 gene coding region fragment, wherein the DNA sequence of the primer P1 is shown as SEQ ID NO.2, and the DNA sequence of the primer P2 is shown as SEQ ID NO. 3; the PCR amplification product was ligated with pET30a vectorBamHI andXholi, after enzyme digestion, carrying out T4 ligase connection, transforming, sequencing and identifying a recon; transferring the recombinant into Escherichia coliTransetta（DE3）Carrying out induction culture in the expression strain, and then purifying and renaturing to obtain a recombinant protein rCgDM9CP-6 with an amino acid sequence in a sequence table SEQ ID NO. 1; can be used for preparing medicine for inhibiting gram-positive bacteriaM.luteusApplication in medicine.

Description

DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application
Technical Field
The invention belongs to the technical field of molecular biology, and particularly relates to a DM 9-domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, a preparation method and application.
Background
Oyster (Chang mu Li)Crassostrea gigas) Is an important seawater cultured shellfish. Because crassostrea gigas lacks an adaptive immune defense system, the crassostrea gigas mainly depends on an innate immune system to resist the infection of exogenous pathogenic microorganisms. Due to the increasing deterioration of marine environment in recent years, various diseases caused by bacteria, fungi and viruses are continuously outbreaked in the breeding population of crassostrea gigas, and huge economic losses are caused.
DM9 is a protein containing carbohydrate recognition domain (DM 9) and has effects in resisting fungal and bacterial infection, promoting cell phagocytosis, and regulating immunity. The protein containing the DM9 domain plays an important role in pattern recognition, microorganism agglutination, phagocytosis opsonization, cell agglutination and the like. Expression level of protein containing DM9 structural domain in drosophila during infectionPseudomonas entomophilaThe later is raised remarkably, and other three proteins containing DM9 domain form a complex and participate in phagocytosis of pathogenic microorganisms. In vertebrate fishT. nattereriIn particular, the family of proteins, the natterin, which contains the DM9 domain, has toxicity to human cells, and can cause cellular edema and necrosis, even permanent disability. The protein containing DM9 structural domain of Crassostrea gigas not only can specifically recognize microorganisms and Pathogen-Associated Molecular Patterns (PAMPs), but also can participate in the processes of phagocytosis, killing and clearing of microorganisms. For example, crassostrea gigasCgTwo binding sites of Asp22 and Lys43 in DM9CP-1 protein can be specifically bound to MAN and are used for fungusY. lipolytica、P. pastorisGram-negative bacteriaE. coli、V. splendidusAnd gram-positive bacteriaS. aureusHas recognition binding activity and can be combined with MAN;CgDM9CP-2 has the activity of agglutinating various microorganisms and binding various PAMPs, and can be combined with D-Mannose, LPS and PGN.
However, heretoforeNo DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application of crassostrea gigas in inhibiting gram-positive bacteriaM. luteusThe related report of the medicine.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provides a DM9 domain-containing recombinant protein rCgDM 9-9 CP-6 of crassostrea gigas, a preparation method and application.
The technical solution of the invention is as follows: a Concha Ostreae containing DM9 domain recombinant protein rCgDM9CP-6 has amino acid sequence shown in SEQ ID NO. 1.
A preparation method of the DM 9-domain-containing recombinant protein rCgDM 9-9 CP-6 of the crassostrea gigas comprises the following steps in sequence:
a. primers P1 and P2 are used for pairing crassostrea gigasCgCarrying out PCR amplification on the DM9CP-6 gene coding region fragment, wherein the DNA sequence of the primer P1 is shown as SEQ ID NO.2, and the DNA sequence of the primer P2 is shown as SEQ ID NO. 3;
b. the PCR amplification product was ligated with pET30a vectorBamHI andXholi, after enzyme digestion, carrying out T4 ligase connection, transforming, sequencing and identifying a recon;
c. transferring the recombinant into Escherichia coliTransetta(DE 3) carrying out induction culture in the expression strain, then purifying and renaturing to obtain the recombinant protein rCgDM9CP-6 with the amino acid sequence in the sequence table SEQ ID NO. 1.
Application of DM 9-domain-containing recombinant protein rCgDM 9-9 CP-6 of crassostrea gigas in preparation of gram-positive bacteriaM. luteusApplication in medicine.
The DM9 domain-containing recombinant protein rCgDM9CP-6 of the crassostrea gigas of the invention is cloned from a crassostrea gigas cDNA library, has the binding activity of various microorganisms, can obviously improve the gram-negative bacteria phagocytosis rate of crassostrea gigas blood lymphocytes, and can eliminate fungiY. lipolytica、P. pastorisGram-negative bacteriaE. coli、V. splendidusAnd gram-positive bacteriaS. aureusHas recognition and binding activity, and can be combined with gram-positive bacteriaM. luteusA binding is identified. Simultaneously has stronger glycoprotein binding capacity, namely can be combined with MAN and D-Mannose, LPS and PGAnd (4) N is combined.
Drawings
FIG. 1 is a graph showing the effect of detecting the binding activity of recombinant protein rCgDM9CP-6 containing DM9 structural domain of crassostrea gigas to bacteria in the example of the invention.
FIG. 2 is a graph showing the effect of detecting the binding activity of the DM9 domain-containing recombinant protein rCgDM9CP-6 to sugar in crassostrea gigas according to the embodiment of the present invention.
FIG. 3 is a diagram showing the phagocytosis-promoting effect of the DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas according to the embodiment of the present invention.
Detailed Description
The preparation method of the DM9 domain-containing recombinant protein CgDM9CP-6 of the crassostrea gigas comprises the following steps in sequence:
1. construction of recombinant vectors
The embodiment of the invention adopts a recombinant vector which is a pET-30a (+) prokaryotic expression vector of Novagen company. By PCR technique, respectively add at 5' endBamHI andXholi restriction site primers P1 and P2 for Crassostrea gigasCgThe DM9CP-6mRNA coding region is amplified, the DNA sequence of the primer P1 is shown as SEQ ID NO.2, and the DNA sequence of the primer P2 is shown as SEQ ID NO. 3.
The PCR reaction conditions are as follows: first, pre-denaturation at 94 ℃ for 5 min, then the following cycle was entered: denaturation at 94 ℃ for 30s, annealing at 56 ℃ for 30s, extension at 72 ℃ for 2 min, 30 cycles in total, and final extension at 72 ℃ for 10 min; purifying and recovering the amplified fragment by agarose gel electrophoresis, and connecting the amplified fragment with a pMD19-T vector; screening positive clone after transformation, extracting plasmid, and usingBamHI andXholi, carrying out double enzyme digestion on the plasmid; recovering the target fragment and channelBamHI andXholand (3) connecting the digested expression vector pET-30a (+) to complete the construction of the recombinant plasmid.
2. Recombinant protein rCgDM9CP-6 expression
The constructed recombinant plasmid is transformed and expressed in Escherichia coli Transetta (DE 3), a single clone is selected and inoculated in 200 mL LB liquid culture medium, the speed is 220 rpm, the temperature is 37 ℃ and the culture is carried out until the OD is reached600= 0.4-0.8; adding IPTG (final concentration of 1 mmol/L), continuously culturing for 4 h, centrifuging at 4 deg.C and 10,000 rpm for 5 min, collecting thallus, and freezing at-80 deg.C; all in oneTaking 1 mL of bacterial liquid for centrifugation, discarding the supernatant, adding 80 mu L of water and 20 mu L of 5 Xprotein loading buffer solution, boiling for 10 min at 99 ℃, slightly centrifuging, and detecting an expression product by SDS-PAGE.
3. Recombinant protein rCgDM9CP-6 purification and renaturation
Purifying the expression product by adopting a nickel sepharose FF column to obtain the denatured recombinant protein, and dialyzing and renaturing by using a dialysis buffer solution. The specific operation steps are as follows:
(1) packing the nickel sepharose FF into a column with the volume of 1.6 multiplied by 20 cm and the volume of a column bed being 10 mL;
(2) equilibrating 2-5 bed volumes with buffer I (50 mmol/L Tris-HCl buffer, pH =9.0, 50 mmol/L nacl, 8 mol/L urea) at a flow rate of 2 mL/min;
(3) taking IPTG induced expression cells, resuspending with buffer solution I, carrying out 150W ultrasonic disruption for 30 min, centrifuging at 12,000 rpm and 4 ℃ for 30 min, filtering supernate with a 0.45-micron filter membrane, and passing through a column at the flow rate of 1 mL/min;
(4) washing with a buffer solution I for 2-5 bed volumes at a flow rate of 2 mL/min;
(5) washing with 50 mmol/L imidazole buffer solution I for 2-5 bed volumes at flow rate of 2 mL/min;
(6) eluting the target protein by using a buffer solution I containing 400 mmol/L of imidazole, and collecting;
(7) detecting the expression of the fusion protein by SDS-PAGE;
(8) washing 5 bed volumes with pure water, washing 3 bed volumes with 20% ethanol at a flow rate of 2 mL/min, purifying recombinant protein by placing the column in an environment of 4 deg.C and keeping the recombinant protein in a denatured state, removing urea by dialysis in renaturation buffer solution to allow the protein to be correctly folded again, and recovering the correct conformation. Dialyzing the denatured and purified product with 2 mM reduced glutathione, 0.4 mM oxidized glutathione, 1 mM EDTA, 50 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 1% glycine and urea with reduced gradient, gradually replacing the urea concentration from 6M to 4M, 3M, 2M, 1M and 0M, not adding glycerol when dialyzing to a non-urea dialysate at the last time, dialyzing at 4 ℃ for 12 h each time to obtain the recombinant protein rCgDM9CP-6 containing the DM9 domain of the crassostrea gigas, wherein the amino acid sequence of the obtained recombinant protein rCgDM9CP-6 containing the DM9 domain of the crassostrea gigas is shown as SEQ ID No. 1.
Length: 143 amino acids
Type (2): amino acids
Chain type: single strand
The characteristics are as follows: the molecular weight is 15.9 kDa, the isoelectric point is 7.69, and the molecular weight has two DM9 structural domains.
Experimental example 1: the invention relates to a detection method for the binding activity of a DM 9-domain-containing recombinant protein rCgDM 9-9 CP-6 of crassostrea gigas and bacteria
Based on a western blotting method, the binding activity of the recombinant protein rCgDM9CP-6 to two gram-negative bacteria (vibrio splendidus and escherichia coli), two gram-positive bacteria (micrococcus luteus and staphylococcus aureus) and two fungi, namely yarrowia yeast and pichia pastoris, is detected. The bacterial sources used were as follows: vibrio splendidus (Vibrio splendidus JZ6) Escherichia coli (E.coli) from Beijing culture CollectionEscherichia coli) Staphylococcus aureus (available from Beijing Quanji Co.) (Staphylococcus aureus) Micrococcus luteus (purchased from Beijing culture Collection of microorganisms)Micrococcus luteus) Jervitae Yeast (available from Beijing culture Collection of microorganisms) ((R))Yarrowia lipolyticd) Pichia pastoris (available from Beijing culture Collection)Pichia pastoris GS115) Purchased from Invitrogen.
The specific operation is as follows:
(1) the 6 microorganisms were cultured overnight by the following method: culturing Micrococcus luteus and Escherichia coli in LB culture medium at 37 deg.C for 20 h, culturing Staphylococcus aureus in LB culture medium at 28 deg.C for 20 h, culturing Vibrio splendidus and yarrowia yeast in 2216E culture medium at 28 deg.C for 20 h, and culturing Pichia yeast in YPD culture medium at 28 deg.C for 20 h;
(2) the cells were collected by centrifugation, resuspended in TBS buffer and adjusted to a cell concentration of 1X 108 CFU/mL；
(3) Sucking 100 mu L of microorganism suspension and equal volume of recombinant protein r obtained in the embodiment of the inventionCgMixing DM9CP-6, and rotary incubating at room temperature for 30 min;
(4) centrifuging at 10,000 rpm for 2 min, collecting thallus, and washing thallus with TBS buffer solution for four times;
(5) after washing, collecting the thalli, and using 40 mu L of sterile water for resuspension;
(6) adding 10 μ L of 5 × protein electrophoresis buffer solution, heating at 99 deg.C for 10 min, and separating protein sample by SDS-PAGE electrophoresis;
(7) after electrophoresis is finished, taking down the gel, cutting an NC membrane and filter paper with the same size, immersing the NC membrane and the filter paper into an electric transfer buffer solution, and standing for 10 min;
(8) sequentially placing filter paper, NC membrane, gel and filter paper into an electrotransformation instrument from top to bottom, setting corresponding current according to the area of gel block, and transferring the membrane for 25 min;
(9) taking out the NC membrane, washing three times by using TBS buffer solution, and each time for 5 min;
(10) washing three times with buffer TBST for 5 min each time;
(11) placing the NC membrane into 5% skimmed milk powder (dissolved in TBST), and sealing at room temperature for 2 h;
(12) taking out the NC membrane, and washing the NC membrane for three times for 5 min each time by using TBST buffer solution;
(13) immersing the NC membrane into a His-tagged monoclonal antibody (purchased from Shanghai Biotech) solution (5% skimmed milk powder and TBST buffer solution) diluted in proportion, and incubating for 1 h at room temperature;
(14) the NC membrane was removed and washed three times with TBST buffer for 5 min each.
(15) Placing the NC membrane into a goat anti-mouse HRP secondary antibody (purchased from Shanghai Biotechnology) solution (5% skimmed milk powder TBST buffer) diluted according to a proportion, and incubating for 1 h at room temperature;
(16) taking out the NC membrane, and washing the NC membrane for three times for 10 min each time by using TBST buffer solution;
(17) ECL method development, imager record western blotting results, as shown in FIG. 1.
The result shows that the recombinant protein rCgDM9CP-6 containing the DM9 structural domain of the crassostrea gigas has binding activity of different degrees on gram-negative bacteria, gram-positive bacteria and fungi, and the binding activity on vibrio splendidus, micrococcus luteus and yarrowia yeast is higher than that on staphylococcus aureus, escherichia coli and pichia yeast. No band was evident in the rTrx negative control group.
Experimental example 2: the invention discloses a detection method for the binding activity of DM 9-containing structural domain recombinant protein rCgDM 9-9 CP-6 and sugar of crassostrea gigas
The combination condition of the DM 9-domain-containing recombinant protein rCgDM9CP-6 of the crassostrea gigas and various PAMPs is detected by an enzyme-linked immunosorbent assay (ELISA). The four sugars D-Mannose, LPS and PGN used were purchased from Sigma.
The specific operation steps are as follows:
(1) mixing Na2CO3With NaHCO3Preparing a coating solution with the pH value of 7.6 according to the concentrations of 15 mmol/L and 35 mmol/L, dissolving four sugars of D-Mannose, LPS and PGN to adjust the concentration to 125 mu g/mL, then adding 100 mu L of the coating solution to each hole of an enzyme label plate, and refrigerating at 4 ℃ overnight;
(2) discarding the coating liquid and washing with TBS-T for 4 times, each time for 4 min;
(3) cleaning, adding 250 μ L of 3% BSA into the holes, and sealing in a constant temperature incubator at 37 ℃ for 1 h;
(4) repeating the step 2 after the sealing is finished;
(5) adding diluted concentration gradient recombinant protein rCgDM9 CP-6100 μ L (rTrx protein is added in negative control, TBS is added in control hole) into each hole, and incubating for 2 h at constant temperature in room;
(6) repeating the step (4);
(7) in each well, the ratio of 1: adding 100 μ L of His tag primary antibody at a ratio of 1,000, and standing at 37 deg.C for 1 h;
(8) the same step (2);
(9) changing the antibody in the step (7) into a secondary HRP antibody and incubating for 1 h in a constant temperature incubator at 37 ℃;
(10) washing each well with TBST for 5 times, 3 min each time;
(11) after developing the color for about 30 min with the TMB developing solution, 45.65. mu.L of a stopping solution (2M HCl) was added to stop the development, and then the OD was measured595The results are shown in FIG. 2.
The result shows that the recombinant protein rCgDM9CP-6 containing the DM9 structural domain of the crassostrea gigas of the embodiment of the invention has the binding activity with Mannose, D-Mannose, LPS and PGN, and the recombinant protein rCgDM9CP-6 has the strongest affinity for Mannose and D-Mannose (P)N = 8.1; 7.9) and relatively weak affinity to LPS (P/N =3.15) and affinity to PGN (P/N = 2.49). And the recombinant protein rCgDM9CP-6 has affinity with Mannose, D-Mannose, LPS and PGN as the recombinant protein rCgDM9CP-6 was increased in concentration. While the negative control rTrX had no binding activity to any of the above four sugars.
Experimental example 3: the invention discloses a method for detecting the phagocytosis promoting activity of DM 9-containing structural domain recombinant protein rCgDM9CP-6 of crassostrea gigas
Two microorganisms (Vibrio splendidus and Staphylococcus aureus) were labeled with Fluorescein Isothiocyanate (FITC), and then phagocytosis efficiency of the oyster blood lymphocytes was measured using a flow cytometer.
The strain is from the above.
The specific operation is as follows:
(1) culturing the two microorganisms respectively and collecting thalli;
(2) mixing formaldehyde with microorganism, and fixing for 10 min;
(3) centrifuging at 4,000 rpm for 10 min to collect bacteria; 0.1M NaHCO3After three washes, incubate in 0.1M NaHCO with 0.1 mg/mLFITC3Medium, incubate 2 h at 25 ℃ with gentle shaking;
(4) centrifuging and removing a supernatant, and washing the microorganisms to be colorless by using TBS buffer solution;
(5) the cells were resuspended in TBS and adjusted to a concentration of 108 CFU/mL；
(6) Adding anticoagulant in equal proportion to extract hemolymph, filtering with 300 mesh silk, centrifuging at 4 deg.C and 800 rpm for 10 min, and collecting blood cells;
(7) cell concentration was adjusted to 10 using L15 saline cell culture medium6 cells/mL；
(8) The DM9 structural domain-containing recombinant protein rCgDM9CP-6 of the crassostrea gigas obtained in the embodiment of the invention is incubated with cells at the volume ratio of 1:1 for 30 min at room temperature in a dark place;
(9) adding the marked bacterium liquid with the same volume, and incubating for 30 min at room temperature in a dark place;
(10) the number of phagocytes was measured by flow cytometry, and the results are shown in FIG. 3.
The result shows that the recombinant protein rCgDM9CP-6 containing the DM9 structural domain of the crassostrea gigas of the embodiment of the invention has obvious phagocytosis promoting activity on vibrio splendidus and has certain promotion effect on the phagocytosis of staphylococcus aureus.
Sequence listing
<110> university of Dalian ocean
<120> DM9 structural domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, and preparation method and application thereof
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 143
<212> PRT
<213> Crassostrea gigas (Crassostra gigas)
<400> 1
Met Ala Val Trp Val Ser Thr Ser Gly Ser His Ile Pro Glu Asn Ala
1 5 10 15
Ile Arg Ala Gly Tyr Glu Glu Asn Gly Asn Pro Leu Phe Ile Ala Arg
20 25 30
Ala Lys Lys Glu Gly Thr Trp Thr Ser Gly Lys Cys Ser Pro Asn Tyr
35 40 45
Glu Gly Ala Tyr Ile Pro Tyr Asp Gly Lys Glu Phe Ile Val Lys Asp
50 55 60
Tyr Asp Val Leu Val Tyr Pro Ile Asn Ala Val Gly Phe Leu Asp Trp
65 70 75 80
Lys His Ala Ser Gly Gly Asn Val Pro Asp Asn Ala Phe Lys Thr Asp
85 90 95
Lys Asp Leu Tyr Val Gly Arg Ala Asn His Ala Gly Cys Leu Ile Pro
100 105 110
Gly Lys Ile Ser Thr Arg Tyr Lys Val Ala Tyr Met Gly Tyr Gly Leu
115 120 125
Lys Glu His Thr Thr Lys Glu Tyr Glu Val Leu Cys Gln Ile Lys
130 135 140
<210> 2
<211> 33
<212> DNA
<213> Artificial sequence (Artificial)
<220>
<221> misc_feature
<222> (1 )..(33)
<223> primer
<400> 2
cgcggatccc ttgatttgac agaggacttc gta 33
<210> 3
<211> 31
<212> DNA
<213> Artificial sequence (Artificial)
<220>
<221> misc_feature
<222> (1 )..(20)
<223> primer
<400> 3
ccgctcgaga tggcagtgtg ggtatcaaca t 31

Claims (3)

1. A crassostrea gigas recombinant protein rCgDM9CP-6 containing a DM9 structural domain is characterized in that: the amino acid sequence is shown as SEQ ID NO. 1.
2. The preparation method of the DM9 domain-containing recombinant protein rCgDM9CP-6 of the crassostrea gigas as claimed in claim 1, which is characterized by comprising the following steps in sequence:
a. primers P1 and P2 are used for pairing crassostrea gigasCgThe DM9CP-6 gene coding region fragment is subjected to PCR amplification, the DNA sequence of the primer P1 is shown as SEQ ID NO.2, and the DNA sequence of the primer P2As shown in SEQ ID NO. 3;
b. the PCR amplification product was ligated with pET30a vectorBamHI andXholi, after enzyme digestion, carrying out T4 ligase connection, transforming, sequencing and identifying a recon;
c. transferring the recombinant into Escherichia coliTransetta(DE 3) carrying out induction culture in the expression strain, then purifying and renaturing to obtain the recombinant protein rCgDM9CP-6 with the amino acid sequence in the sequence table SEQ ID NO. 1.
3. The use of the DM9 domain-containing recombinant protein rCgDM9CP-6 of claim 1 in the preparation of gram-positive bacteriaM. luteusApplication in medicine.
CN202110539350.5A 2021-05-18 2021-05-18 DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application Pending CN113185593A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110539350.5A CN113185593A (en) 2021-05-18 2021-05-18 DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110539350.5A CN113185593A (en) 2021-05-18 2021-05-18 DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application

Publications (1)

Publication Number Publication Date
CN113185593A true CN113185593A (en) 2021-07-30

Family

ID=76982560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110539350.5A Pending CN113185593A (en) 2021-05-18 2021-05-18 DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application

Country Status (1)

Country Link
CN (1) CN113185593A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055250A1 (en) * 2021-10-01 2023-04-06 University Of Belgrade Carbohydrate binding polypeptide of savalia savaglia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936106A (en) * 2017-12-25 2018-04-20 大连海洋大学 Long oyster domain protein containing DM9 CgDM9CP 4, preparation method and application
CN108003233A (en) * 2017-12-25 2018-05-08 大连海洋大学 Long oyster domain protein containing DM9 CgDM9CP-2, preparation method and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936106A (en) * 2017-12-25 2018-04-20 大连海洋大学 Long oyster domain protein containing DM9 CgDM9CP 4, preparation method and application
CN108003233A (en) * 2017-12-25 2018-05-08 大连海洋大学 Long oyster domain protein containing DM9 CgDM9CP-2, preparation method and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUAI JIANG ET AL.: ""DM9 Domain Containing Protein Functions As a Pattern Recognition Receptor with Broad Microbial Recognition Spectrum"", 《FRONTIERS IN IMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055250A1 (en) * 2021-10-01 2023-04-06 University Of Belgrade Carbohydrate binding polypeptide of savalia savaglia

Similar Documents

Publication Publication Date Title
CN110643612B (en) Trachinotus ovatus antimicrobial peptide NK-lysin gene and application thereof
CN111690054B (en) Pinctada martensii Kunitz type serine protease inhibitor gene, encoded protein and application
CN102703483B (en) Recombinant oral protein TAT-GH of tilapia, preparation method for recombinant oral protein TAT-GH and application of recombinant oral protein TAT-GH
CN102191255B (en) Preparation and application of recombinant plectasin
CN101914149A (en) Preparation and application of anti-lipid polysaccharide factor with bacteriostatic activity
CN111499699A (en) Novel coronavirus COVID-19-N protein expression and purification method
CN105169381A (en) Helicobacter pylori multivalent epitope vaccine and preparation method thereof
CN105219779B (en) Red claw crayfish coagulogen and preparation method and application
CN113185593A (en) DM9 domain-containing recombinant protein rCgDM9CP-6 of crassostrea gigas, preparation method and application
CN112851792A (en) Preparation method and application of grass carp TNF-alpha recombinant protein
CN108191964B (en) Apostichopus japonicus F-type lectin AjFL-1, and preparation method and application thereof
CN108003233B (en) Oyster containing DM9 structural domain protein CgDM9CP-2, preparation method and application
CN110408624A (en) A kind of Ruditapes philippinarum c-type agglutinant protein and the preparation method and application thereof
CN113912691B (en) Recombinant crassostrea gigas high mobility group protein r-CgHMGB1, preparation method and application thereof
CN107987154B (en) Ostrea gigas IgSF molecule CgCAICP1 gene recombinant protein, preparation method and application
CN103450355A (en) Recombined bovine alpha interferon and application thereof
CN1936000A (en) Fennero penaeus chinensis antibacterial protein gene and recombinant expression and use
CN107936106B (en) Oyster containing DM9 structural domain protein CgDM9CP-4, preparation method and application
CN110845594A (en) Recombinant serum amyloid protein A capable of enhancing immune response of crassostrea gigas and preparation method thereof
CN113603748B (en) Beta-folded antibacterial peptide HINGE-RV and preparation method and application thereof
CN111690636B (en) Trypsin-like serine protease gene, encoded protein and application
CN114044816B (en) Recombinant crassostrea gigas Jiao Kongsu protein rCgGSDME-N, preparation method and application thereof
CN116854797A (en) Recombinant protein containing DM9 structural domain of eriocheir sinensis and application thereof
CN109762065B (en) Single-domain heavy chain antibody Nb72 for vibrio fluvialis
CN102924583B (en) Hydramacin-1 antimicrobial peptide mutant and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210730